Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

And one clearly comes out on top. Injectable GLP-1 receptor agonist drugs Wegovy (semaglutide) and Zepbound (tirzepatide) have revolutionized weight loss. But, strangely, no one has compared the ...

The SURMOUNT-5 trial, published over the weekend in the New England Journal of Medicine and presented at the European Congress on Obesity, showed that treatment with tirzepatide (Zepbound ... can ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

2:12 Health Matters: Eli Lilly launches single-dose vials weigh- loss drug to expand supply People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 per cent more weight than those using ...

findings from a real-world electronic medical record study found adults with obesity using tirzepatide (Zepbound, Eli Lilly) were more likely to lose 5%, 10% or 15% of their body weight than those ...

In 2022, for example, Dr. Aronne led a study showing that a 72-week course of tirzepatide at its maximum dosage reduced body weight by 20.9%; a similar study published in 2021 reported a 14.9% ...

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. The tirzepatide group trimmed about 7 ...